EP1563073A2 - Procedes de production de proteine et cellules modifiees pour utilisation dans ces procedes - Google Patents

Procedes de production de proteine et cellules modifiees pour utilisation dans ces procedes

Info

Publication number
EP1563073A2
EP1563073A2 EP03739320A EP03739320A EP1563073A2 EP 1563073 A2 EP1563073 A2 EP 1563073A2 EP 03739320 A EP03739320 A EP 03739320A EP 03739320 A EP03739320 A EP 03739320A EP 1563073 A2 EP1563073 A2 EP 1563073A2
Authority
EP
European Patent Office
Prior art keywords
cell
bci
protein
cells
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03739320A
Other languages
German (de)
English (en)
Other versions
EP1563073A4 (fr
Inventor
Gisela Chiang
William Sisk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Publication of EP1563073A2 publication Critical patent/EP1563073A2/fr
Publication of EP1563073A4 publication Critical patent/EP1563073A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des cellules possédant une quantité augmentée de protéine Bcl-xL et leur utilisation en production de protéine.
EP03739320A 2002-06-26 2003-06-26 Procedes de production de proteine et cellules modifiees pour utilisation dans ces procedes Withdrawn EP1563073A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39173802P 2002-06-26 2002-06-26
US391738P 2002-06-26
US44049803P 2003-01-16 2003-01-16
US440498P 2003-01-16
PCT/US2003/020207 WO2004003151A2 (fr) 2002-06-26 2003-06-26 Procedes de production de proteine et cellules modifiees pour utilisation dans ces procedes

Publications (2)

Publication Number Publication Date
EP1563073A2 true EP1563073A2 (fr) 2005-08-17
EP1563073A4 EP1563073A4 (fr) 2007-09-19

Family

ID=30003205

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03739320A Withdrawn EP1563073A4 (fr) 2002-06-26 2003-06-26 Procedes de production de proteine et cellules modifiees pour utilisation dans ces procedes

Country Status (5)

Country Link
EP (1) EP1563073A4 (fr)
JP (2) JP2006503555A (fr)
AU (2) AU2003245702A1 (fr)
CA (1) CA2491212A1 (fr)
WO (1) WO2004003151A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100454016B1 (ko) * 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
EP2209891A1 (fr) * 2007-11-13 2010-07-28 Boehringer Ingelheim Pharma GmbH & Co. KG Amélioration de la capacité sécrétoire dans des cellules hôtes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1348758A1 (fr) * 2002-03-28 2003-10-01 Boehringer Ingelheim Pharma GmbH & Co.KG Cellules hôtes ayant des propriétés de survie améliorées et procédé pour produire ces cellules
EP1468079A1 (fr) * 2002-01-05 2004-10-20 Korea Advanced Institute of Science and Technology Lignee cellulaire cho deficiente en dhfr transfectee avec un gene anti-apoptotique, sa methode de preparation et methode de production d'une proteine cible au moyen de ladite lignee cellulaire

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6163196A (en) * 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
US6218181B1 (en) * 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1468079A1 (fr) * 2002-01-05 2004-10-20 Korea Advanced Institute of Science and Technology Lignee cellulaire cho deficiente en dhfr transfectee avec un gene anti-apoptotique, sa methode de preparation et methode de production d'une proteine cible au moyen de ladite lignee cellulaire
EP1348758A1 (fr) * 2002-03-28 2003-10-01 Boehringer Ingelheim Pharma GmbH & Co.KG Cellules hôtes ayant des propriétés de survie améliorées et procédé pour produire ces cellules

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CHIANG GISELA G ET AL: "Bcl-x(L) mediates increased production of humanized monoclonal antibodies in chinese hamster ovary cells" BIOTECHNOLOGY AND BIOENGINEERING, vol. 91, no. 7, September 2005 (2005-09), pages 779-792, XP002446137 ISSN: 0006-3592 *
FIGUEROA B ET AL: "A COMPARISON OF THE PROPERTIES OF A BCL-XL VARIANT TO THE WILD-TYPE ANTI-APOPTOSIS INHIBITOR IN MAMMALIAN CELL CULTURES" METABOLIC ENGINEERING, ACADEMIC PRESS,, US, vol. 5, no. 4, October 2003 (2003-10), pages 230-245, XP008064154 ISSN: 1096-7176 *
FUSSENEGGER M ET AL: "CONTROLLED PROLIFERATION BY MULTIGENE METABOLIC ENGINEERING ENHANCES THE PRODUCTIVITY OF CHINESE HAMSTER OVARY CELLS" NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 16, no. 5, May 1998 (1998-05), pages 468-472, XP001093788 ISSN: 1087-0156 *
FUSSENEGGER M. ET AL: "Regulated overexpression of the survival factor bcl-2 in CHO cells increases viable cell density in batch culture and decreases DNA release in extended fixed-bed cultivation" CYTOTECHNOLOGY, vol. 32, no. 1, 1 January 2000 (2000-01-01), pages 45-61, XP002326419 KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL *
GOSWAMI J ET AL: "Apoptosis in batch cultures of Chinese hamster ovary cells" BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 62, no. 6, 20 March 1999 (1999-03-20), pages 632-640, XP002326418 ISSN: 0006-3592 *
JOEL CHARBONNEAU ET AL: "Protection of hybridoma cells against apoptosis by a loop domain-deficient Bcl-xL protein" CYTOTECHNOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 37, no. 1, 1 September 2001 (2001-09-01), pages 41-47, XP019236711 ISSN: 1573-0778 *
JUNG D. ET AL: "Inducible expression of Bcl-XL restricts apoptosis resistance to the antibody secretion phase in hybridoma cultures" BIOTECHNOLOGY AND BIOENGINEERING, vol. 79, no. 2, 21 May 2002 (2002-05-21), - 20 July 2002 (2002-07-20) pages 180-187, *
KIM N S ET AL: "Overexpression of bcl-2 inhibits sodium butyrate-induced apoptosis in Chinese hamster ovary cells resulting in enhanced humanized antibody production" BIOTECHNOLOGY AND BIOENGINEERING - COMBINATORIAL CHEMISTRY, WILEY, NEW YORK, NY, US, vol. 71, no. 3, 2000, pages 184-193, XP002208594 *
MASTRANGELO A J ET AL: "Part II. Overexpression of bcl-2 family members enhances survival of mammalian cells in response to various culture insults" BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 67, no. 5, 5 March 2000 (2000-03-05), pages 555-564, XP002326420 ISSN: 0006-3592 *
MASTRANGELO ALISON J ET AL: "Part I. Bcl-2 and bcl-xL limit apoptosis upon infection with alphavirus vectors" BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 67, no. 5, 5 March 2000 (2000-03-05), pages 544-554, XP002217633 ISSN: 0006-3592 *
MEENTS H ET AL: "Impact of coexpression and coamplification of sICAM and antiapoptosis determinants bcl-2/bcl-x(L) on productivity, cell survival, and mitochondria number in CHO-DG44 grown in suspension and serum-free media" BIOTECHNOLOGY AND BIOENGINEERING, WILEY & SONS, HOBOKEN, NJ, US, vol. 80, no. 6, 20 December 2002 (2002-12-20), pages 706-716, XP002251640 ISSN: 0006-3592 *
See also references of WO2004003151A2 *
ZANGHI JAMES A ET AL: "Serum protects protein-free competent Chinese hamster ovary cells against apoptosis induced by nutrient deprivation in batch culture" BIOTECHNOLOGY AND BIOENGINEERING, vol. 64, no. 1, 5 July 1999 (1999-07-05), pages 108-119, XP002446136 ISSN: 0006-3592 *

Also Published As

Publication number Publication date
WO2004003151A2 (fr) 2004-01-08
JP2006503555A (ja) 2006-02-02
AU2010201256A1 (en) 2010-04-22
CA2491212A1 (fr) 2004-01-08
JP2011004771A (ja) 2011-01-13
WO2004003151A3 (fr) 2005-06-23
AU2003245702A1 (en) 2004-01-19
EP1563073A4 (fr) 2007-09-19

Similar Documents

Publication Publication Date Title
EP1254216B1 (fr) Amelioration de la galactosylation de glycoproteines de recombinaison
EP2300600B1 (fr) Procédés pour améliorer la viabilité et la productivité dans une culture cellulaire
CA2480684C (fr) Cellules hotes presentant des proprietes de survie cellulaire ameliorees, et procede de production de telles cellules
EP2707488B1 (fr) Amélioration du rendement de la production des protéines médiée par une gtpase de cdc42 à cyclage rapide
EP2010565A1 (fr) Procédé de production de protéine recombinante dans des cellules cho
US9340592B2 (en) CHO/CERT cell lines
AU2010201256A1 (en) Protein Production Methods and Modified Cells for Use Therein
Lee et al. Development of apoptosis‐resistant dihydrofolate reductase‐deficient Chinese hamster ovary cell line
KR20090112725A (ko) 세포 성장의 증진방법
US20030219871A1 (en) Host cells having improved cell survival properties and methods to generate such cells
AU744484B2 (en) Method for increasing secretion of proteins in eukaryotic host cells
WO2001059075A9 (fr) Amelioration concernant la sialylation de glycoproteines
WO2022229854A1 (fr) Cellules hypersialylées
JP2012125197A (ja) タンパク質の生産方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050118

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1081989

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20070822

17Q First examination report despatched

Effective date: 20071213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20101014

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1081989

Country of ref document: HK